Animeloxan
General data
Product class:
Authorized package
Medicinal product class:
Veterinary medicine
Package code:
1785865
Name of medicinal product:
Animeloxan
Active substances:
Meloxicam
Estonian
,
English
,
Latin
ATC code:
QM01AC06
Dosage form:
solution for injection
Route of administration:
subcutaneous use; intramuscular use; intravenous use
Strengh:
20mg 1ml
Amount in package:
100ml 1TK
Legal status for supply*:
Subject to medicinal prescription
Class of active substance:
Additional information:
Indication:
Cattle: For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain following dehorning in calves. Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy Horses: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. For the relief of pain associated with equine colic.
Safety features:
No
Summary of product characteristics (SPC):
(last updated 24 July 2023)
Package information leaflet (PIL):
EST
(last updated 24 July 2023)
Labelling:
(last updated 24 September 2019)
Withdrawal time:
Veis: Lihale ja söödavatele kudedele: 15 päeva Piimale: 5 päeva Siga: Lihale ja söödavatele kudedele: 8 päeva Hobune: Lihale ja söödavatele kudedele: 5 päeva Ei ole lubatud kasutamiseks hobustel, kelle piima tarvitatakse inimtoiduks.
Species:
veis, siga, hobune
Last imported to Estonia:
20 February 2023
Marketing authorization
Marketing authorization holder:
aniMedica GmbH
Marketing authorization number:
2199
Marketing authorization issued on:
24 September 2019
Marketing authorization expires on:
24 September 2024
Marketing authorization procedure type:
Mutual recognition
Entry/Changing date: 24 July 2023
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription